COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer

被引：0

作者：

I P M Tomlinson

M Dunlop

H Campbell

B Zanke

S Gallinger

T Hudson

T Koessler

P D Pharoah

I Niittymäkix

S Tuupanenx

L A Aaltonen

K Hemminki

A Lindblom

A Försti

O Sieber

L Lipton

T van Wezel

H Morreau

J T Wijnen

P Devilee

K Matsuda

Y Nakamura

S Castellví-Bel

C Ruiz-Ponte

A Castells

A Carracedo

J W C Ho

P Sham

R M W Hofstra

P Vodicka

H Brenner

J Hampe

C Schafmayer

J Tepel

S Schreiber

H Völzke

M M Lerch

C A Schmidt

S Buch

V Moreno

C M Villanueva

P Peterlongo

P Radice

M M Echeverry

A Velez

L Carvajal-Carmona

R Scott

S Penegar

P Broderick

A Tenesa

机构：

[1] Molecular and Population Genetics,Nuffield Department of Medicine

[2] University of Oxford,Department of Oncology

[3] Wellcome Trust Centre for Human Genetics,Department of Medical Genetics

[4] Institute of Genetics and Molecular Medicine,Department of Molecular Medicine and Surgery

[5] University of Edinburgh,Department of Pathology

[6] MRC-HGU,Departments of Human and Clinical Genetics

[7] Western General Hospital,Department of Gastroenterology

[8] Public Health Sciences,Department of Genetics

[9] University of Edinburgh,Division of Clinical Epidemiology and Aging Research

[10] The Ontario Institute for Cancer Research,Department of General Internal Medicine

[11] The MaRS Center,Department of General and Thoracic Surgery

[12] The University of Ottawa Faculty of Medicine,Departamento de Biología

[13] Cancer Care Ontario,Departamento de Patología

[14] Samuel Lunenfeld Research Institute,undefined

[15] Mount Sinai Hospital and University of Toronto,undefined

[16] University of Cambridge,undefined

[17] Genome-Scale Biology Research Program,undefined

[18] Biomedicum 9,undefined

[19] University of Helsinki,undefined

[20] German Cancer Research Center,undefined

[21] Karolinska Institutet,undefined

[22] CMM02,undefined

[23] LCCI Biomarker Laboratory,undefined

[24] Ludwig Institute for Cancer Research,undefined

[25] PO Box 2008,undefined

[26] Royal Melbourne Hospital,undefined

[27] Leiden University Medical Center,undefined

[28] Leiden University Medical Center,undefined

[29] Laboratory of Molecular Medicine,undefined

[30] Human Genome Center,undefined

[31] Institute of Medical Science,undefined

[32] The University of Tokyo,undefined

[33] Institut de Malalties Digestives i Metabòliques,undefined

[34] Hospital Clínic,undefined

[35] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd),undefined

[36] IDIBAPS,undefined

[37] University of Barcelona,undefined

[38] Fundacion Publica Galega de Medicina Xenomica (FPGMX),undefined

[39] CIBERER,undefined

[40] Genomic Medicine Group-University of Santiago de Compostela,undefined

[41] The University of Hong Kong,undefined

[42] University Medical Center Groningen,undefined

[43] University of Groningen,undefined

[44] Institute of Experimental Medicine,undefined

[45] Academy of Sciences of the Czech Republic,undefined

[46] German Cancer Research Center,undefined

[47] University Hospital,undefined

[48] Schleswig-Holstein,undefined

[49] POPGEN Biobank,undefined

[50] University Hospital Schleswig-Holstein,undefined

来源：

British Journal of Cancer | 2010年 / 102卷

关键词：

colorectal cancer; association; polymorphism;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

It is now recognised that a part of the inherited risk of colorectal cancer (CRC) can be explained by the co-inheritance of low-penetrance genetic variants. The accumulated experience to date in identifying these variants has served to highlight difficulties in conducting statistically and methodologically rigorous studies and follow-up analyses. The COGENT (COlorectal cancer GENeTics) consortium includes 20 research groups in Europe, Australia, the Americas, China and Japan. The overarching goal of COGENT is to identify and characterise low-penetrance susceptibility variants for CRC through association-based analyses. In this study, we review the rationale for identifying low-penetrance variants for CRC and our proposed strategy for establishing COGENT.

引用

页码：447 / 454

页数：7

共 564 条

[1]

Aaltonen L(2007)Explaining the familial colorectal cancer risk associated with mismatch repair (MMR)-deficient and MMR-stable tumors Clin Cancer Res 13 356-361

[2]

Johns L(2007)A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk Nat Genet 39 1315-1317

[3]

Jarvinen H(2007)EPICOLON project: contribution to the knowledge of Lynch syndrome and other familial or hereditary colorectal cancer Med Clin (Barc) 128 55-60

[4]

Mecklin JP(2006)NAD(P)H:quinone oxidoreductase 1 (NQO1) Pro187Ser polymorphism and the risk of lung, bladder, and colorectal cancers: a meta-analysis Cancer Epidemiol Biomarkers Prev 15 979-987

[5]

Houlston R(2005)Relationship between metabolic enzyme polymorphism and colorectal cancer World J Gastroenterol 11 331-335

[6]

Broderick P(2000)Ontario familial colon cancer registry: methods and first-year response rates Chronic Dis Can 21 81-86

[7]

Carvajal-Carmona L(2002)Low-penetrance genes and their involvement in colorectal cancer susceptibility Cancer Epidemiol Biomarkers Prev 11 1332-1352

[8]

Pittman AM(2005)Colorectal cancer and the CHEK2 1100delC mutation Genes Chromosomes Cancer 43 377-382

[9]

Webb E(2008)Genetic susceptibility to cancer: the role of polymorphisms in candidate genes JAMA 299 2423-2436

[10]

Howarth K(2008)Identification of low penetrance alleles for lung cancer: the GEnetic Lung CAncer Predisposition Study (GELCAPS) BMC Cancer 8 244-157

← 1 2 3 4 5 6 7 8 9 10 →